COVAXIN shows interim vaccine efficacy of 81% in Phase 3 trial: Bharat Biotech

0
69


Bharat Biotech Wednesday said its indigenously developed coronavirus vaccine COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in Phase 3 clinical trial.

The drug major further said first interim analysis is based on 43 cases, of which 36 cases of Covid-19 were observed in the placebo group versus seven cases observed in the COVAXIN group, resulting in a point estimate of vaccine efficacy of 80.6 per cent.

The interim analysis showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups, the company added.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here